An imaging agent has been granted FDA fast track designation. The specific use of the agent varies across reports, with some indicating it is for high-grade glioma surgery, clear cell renal cell carcinoma diagnosis, or interstitial lung disease imaging. The exact agent and its intended use are unclear, with different outlets mentioning different names and applications.